Julia Teply‐Szymanski
Papers
1
Total Citations
40
H-Index
1
About
Dr. Julia Teply‐Szymanski is a leading translational researcher in gynecologic oncology, with a primary focus on homologous recombination deficiency (HRD) as a predictive biomarker in ovarian cancer. Her most cited work, a 2022 study on HRD assessment in a real-world cohort of 514 ovarian carcinoma samples, has garnered 40 citations for its pivotal role in refining next-generation sequencing protocols for BRCA1/BRCA2 and over 26,000 single-nucleotide variants. This research directly impacts clinical decision-making by enabling more precise identification of patients who may benefit from PARP inhibitor therapies. Dr. Teply‐Szymanski’s contributions bridge molecular diagnostics and personalized medicine, advancing the standard of care for ovarian cancer. Her work is widely recognized for its methodological rigor and translational relevance, making her a key voice in the integration of genomic biomarkers into routine oncology practice.
Research Focus
Key Achievements
Top Papers
- 1